Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Is Jumping Today

By Keith Speights - May 17, 2021 at 1:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be increasingly optimistic about the outlook for its drug Orladeyo.

What happened

Shares of BioCryst Pharmaceuticals (BCRX 1.88%) were 8.1% higher as of 12:18 p.m. EDT on Monday after rising as much as 10.5% earlier in the day. The gain reflects continued momentum following BioCryst's announcement last week of U.K. approval of Orladeyo in preventing recurrent hereditary angioedema (HAE) attacks.

So what

Today's nice gain for the biotech stock probably has less to do with the U.K. approval itself. It's likely more reflective of investors' overall optimism about Orladeyo's prospects.

Man wearing coat and tie with thumb up

Image source: Getty Images.

BioCryst reported U.S. sales of $10.9 million for the HAE drug in the first quarter of 2021. That's a really good start for Orladeyo's first full quarter after its U.S. launch. 

Now what

Look for Orladeyo sales outside the U.S. to become increasingly important, and not just because of the U.K. approval. The company won European Commission approval for the drug in late April. It plans to launch Orladeyo in Germany first, followed by launches in other European markets. BioCryst's partner Torii began selling the HAE drug in Japan in April as well. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$14.64 (1.88%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.